Dna Or Rna Fragments Or Modified Forms Thereof (e.g., Genes, Etc.) Patents (Class 536/23.1)
  • Patent number: 10995334
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: May 4, 2021
    Assignee: CuRNA Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Patent number: 10994026
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: May 4, 2021
    Assignee: Friedrich Miescher Institute for Biomedical Research
    Inventors: Dominik Hartl, Josephine Juettner, Arnaud Krebs, Botond Roska, Dirk Schuebeler
  • Patent number: 10982207
    Abstract: The invention is a novel method of isolating long nucleic acids from samples suitable for nucleic acid sequencing. The method is especially suitable for isolating low-concentration nucleic acids, e.g., viral nucleic acids, from clinical samples.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: April 20, 2021
    Assignee: Roche Sequencing Solutions, Inc.
    Inventors: Monica Herrera, Jenny A. Johnson, Yuan Qin, Kunchala Rungsrisuriyachai, Smriti Sharma
  • Patent number: 10976321
    Abstract: Provided is a method of assaying for an analyte, including combining a test sample having the analyte, with a calibration sample having at least two different aliquots of the analyte, each aliquot having a different known quantity of the analyte. The test sample and each aliquot are differentially labeled with one or more isobaric mass labels each with a mass spectrometrically distinct mass marker group, such that the test sample and each aliquot of the calibration sample can be distinguished by mass spectrometry. The method further includes determining by mass spectrometry the quantity of analyte in the test sample and in each aliquot, and calibrating the quantity of analyte in the test sample against known and determined quantities of analytes in the aliquots.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: April 13, 2021
    Assignee: ELECTROPHORETICS LIMITED
    Inventors: Peter Schulz-Knappe, Ian Pike, Karsten Kuhn
  • Patent number: 10968486
    Abstract: The present invention provides a composition, a kit and the use thereof, as well as the method for detecting the cell proliferative abnormality in individuals or grading the disease degree in the individuals. The composition comprises nucleic acids for detecting the methylation level within at least one target region of a gene and the fragment thereof.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: April 6, 2021
    Assignees: Biochain Institute, Inc., Biochain (Beijing) Science & Technology, Inc.
    Inventors: Xiaoliang Han, Tong Lu, James Jianming Wang
  • Patent number: 10961184
    Abstract: Disclosed are dendritic anionic lipids which are compounds of Formula (I): wherein R and R1 are non-polar groups, L is a linking moiety, and Dm is a dendritic moiety of m generations, each as defined herein. These dendritic anionic lipids are useful for delivery and expression of m RNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: March 30, 2021
    Assignee: Translate Bio, Inc.
    Inventors: Michael Heartlein, Frank DeRosa, Shrirang Karve
  • Patent number: 10947535
    Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: March 16, 2021
    Assignee: Research Foundation of the City University of New York
    Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
  • Patent number: 10918709
    Abstract: The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: February 16, 2021
    Assignee: EYEGENE INC.
    Inventors: Yang Je Cho, Kwangsung Kim, Na Gyong Lee, Shin Ae Park
  • Patent number: 10907218
    Abstract: The present invention provides methods and compositions for determining the presence and/or amount of pathogenic Leptospira in a test sample. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting pathogenic Leptospira nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the Leptospira assay.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: February 2, 2021
    Assignee: Quest Diagnostics Investments LLC
    Inventor: Erik P. Johnson
  • Patent number: 10906949
    Abstract: Provided herein are compositions, systems, kits, and methods for treating nervous system injuries caused by trauma or neurodegeneration or aging in a subject by administering a CSPG or SOCS3 reduction peptide (CRP and SRP respectively), or a nucleic acid sequence encoding the CRP or SRP, wherein both the CRP and SRP comprise a cell membrane penetrating domain, and a lysosome targeting domain, and the CRP further comprises a chondroitin sulfate proteoglycan (CSPG) binding domain, and the SRP further comprises a suppressor of cytokine signaling-3 (SOCS3) binding domain.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: February 2, 2021
    Assignee: The Cleveland Clinic Foundation
    Inventors: Yu-Shang Lee, Ching-Yi Lin
  • Patent number: 10911810
    Abstract: The non-linear content scheduling and encoding (recording) system provides a highly automated file-based video-on-demand (VOD) publishing workflow. The system includes content-provider scheduling and broadcast programming for encoding, editing, and distribution of video assets (e.g., episodes). The invention effectively scales VOD production and allows broadcasters to use the same schedule and sources as their traditional playout operation to quickly and efficiently produce VOD deliverables with all the correct metadata. The systems of the invention process content at significantly faster rates than traditional, real-time VOD generation. The systems provide program management and incorporate traffic system ad components within fully integrated VOD publishing. The systems enable automatic retrieval of sources for VOD generation from generic storage, video servers, non-linear editing systems, archiving systems, content delivery systems, data or video tapes, as well as from live video sources.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: February 2, 2021
    Assignee: SCRIPPS NETWORKS INTERACTIVE, INC.
    Inventors: Graham Cole, Kevin Barry, Michael Donovan, Tim Harty
  • Patent number: 10898588
    Abstract: Disclosed herein are recombinant viral vectors comprising a liver specific promotor in operable combination with a heterologous nucleic acid sequence encoding a protein, such as a clotting factor. Methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B, are also provided.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: January 26, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Christopher B. Doering, H. Trent Spencer, Harrison C. Brown
  • Patent number: 10900033
    Abstract: Methods for capturing a target nucleic acid from a sample by using a capture probe that binds nonspecifically to the target nucleic acid and binds specifically to an immobilized probe via a specific binding pair that has one member on the capture probe and one member on the immobilized probe are disclosed. Compositions that include a capture probe that binds nonspecifically to a target nucleic acid and specifically to an immobilized probe via binding of members of a specific binding pair in a solution phase of a reaction mixture are disclosed.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: January 26, 2021
    Assignee: Gen-Probe Incorporated
    Inventors: Michael M. Becker, Mehrdad R. Majlessi
  • Patent number: 10894957
    Abstract: The present teachings relate to the extraction of nucleic acid from solid materials. Provided are useful compositions, methods and kits for obtaining nucleic acids from a solid biological sample or an adhesive material having a biological material adherent or embedded within the adhesive substrate. The extracted nucleic acid can be used in downstream applications such as genotyping, detection, quantification, and identification of the source of the biological material.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: January 19, 2021
    Assignee: Life Technologies Corporation
    Inventors: James Stray, Jason Yingjie Liu, Maxim Brevnov, Jaiprakash Shewale, Allison Holt
  • Patent number: 10889812
    Abstract: The present invention provides isolated nucleic acid molecules comprising short non-coding protein regulatory RNAs (sprRNA), variants, fragments and inhibitors thereof and compositions and methods of using the same.
    Type: Grant
    Filed: October 24, 2015
    Date of Patent: January 12, 2021
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Li Mao, Yuping Mei
  • Patent number: 10888579
    Abstract: Compositions and methods for reducing susceptibility to infectious disease in bees using RNA interference technology, and more particularly, prevention and treatment of viral infections in honeybees such as Israel acute paralysis virus (IAPV) by feeding of pathogen-specific dsRNA. Further, multiple-pathogen specific dsRNA is disclosed.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: January 12, 2021
    Assignee: BEEOLOGICS INC.
    Inventors: Nitzan Paldi, Gal Yarden
  • Patent number: 10876121
    Abstract: Disclosed herein are molecules and pharmaceutical compositions that mediate RNA interference against EGFR. Also described herein include methods for treating a disease or disorder that comprises a molecule or a pharmaceutical composition that mediate RNA interference against EGFR.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: December 29, 2020
    Assignee: AVIDITY BIOSCIENCES, INC.
    Inventor: Hanhua Huang
  • Patent number: 10869940
    Abstract: Provided herein are targeted photoacoustic compounds and formulations thereof that can contain a photoacoustic signaling moiety operatively coupled to a targeting moiety. Also provided herein are methods of imagining a subject using the targeted photoacoustic compounds and formulations thereof provided herein.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: December 22, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Sanjiv S. Gambhir, Jelena Levi
  • Patent number: 10870849
    Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: December 22, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Bob Dale Brown
  • Patent number: 10842855
    Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: November 24, 2020
    Assignee: DUKE UNIVERSITY
    Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
  • Patent number: 10837013
    Abstract: The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: November 17, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Bob Dale Brown
  • Patent number: 10800805
    Abstract: Protected fluorescent reagent compounds and their methods of synthesis are provided. The compounds are useful in various fluorescence-based analytical methods, including the analysis of highly multiplexed optical reactions in large numbers at high densities, such as single molecule real time nucleic acid sequencing reactions. The compounds contain fluorescent dye elements, that allow the compounds to be detected with high sensitivity at desirable wavelengths, binding elements, that allow the compounds to be recognized specifically by target biomolecules, and protective shield elements, that decrease undesirable contacts between the fluorescent dye elements and the bound target biomolecules and that therefore decrease photodamage of the bound target biomolecules by the fluorescent dye elements.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: October 13, 2020
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Lubomir Sebo, Jeremiah Hanes, Gene Shen, Louis Brogley, Stephen Yue, Frank Zheng, Yuri Lapin, John Lyle, Honey Osuna, Andrei Fedorov
  • Patent number: 10793859
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: October 6, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Sergei Gryaznov, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Saul Martinez Montero, Jin Hong, Rajendra K. Pandey, Vivek Kumar Rajwanshi, Lakshmipathi Pandarinathan, Yi Jin, Bharat Baral
  • Patent number: 10793869
    Abstract: The present invention provides molecular constructs and methods for use thereof, including constructs including heterologous miRNA recognition sites, constructs for gene suppression including a gene suppression element embedded within an intron flanked on one or on both sides by non-protein-coding sequence, constructs containing engineered miRNA or miRNA precursors, and constructs for suppression of production of mature microRNA in a cell. Also provided are transgenic plant cells, plants, and seeds containing such constructs, and methods for their use. The invention further provides transgenic plant cells, plants, and seeds containing recombinant DNA for the ligand-controlled expression of a target sequence, which may be endogenous or exogenous. Also disclosed are novel miRNAs and miRNA precursors from crop plants including maize and soy.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 6, 2020
    Assignee: MONSANTO TECHNOLOGY LLC
    Inventors: Edwards M. Allen, Larry A Gilbertson, Sara E. Heisel, Shihshieh Huang, Elysia K. Krieger, Thomas M. Malvar
  • Patent number: 10793865
    Abstract: A prokaryotic protein appearing to have a Bin/Amphiphysin/Rvs (BAR) domain, previously known in eukaryotes, has been identified. Expression of this protein causes formation of outer membrane extensions.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: October 6, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Daniel A. Phillips, Sarah M. Glaven
  • Patent number: 10780051
    Abstract: Methods and compositions for serum-stabilizing micelles for drug delivery or imaging agent delivery are provided, as well as methods and compositions to enhance micelle-mediated drug delivery. This invention provides a process for synthesizing a lipid micelle comprising one or more lipid-oligonucleotide conjugate molecules, the process comprising contacting an amount of lipid molecules with an amount of lipid-oligonucleotide conjugate molecules sufficient to create a lipid micelle comprising lipid-oligonucleotide conjugate molecules.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: September 22, 2020
    Assignee: Albert Einstein College of Medicine
    Inventors: Samantha E. Wilner, Matthew Levy
  • Patent number: 10781477
    Abstract: Disclosed herein are compositions, kits, methods, and systems for detecting a target molecule in a sample using a detection molecule.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: September 22, 2020
    Assignee: ARATOME, LLC
    Inventors: Jay Trautman, Gordon Wang, David Lenzi
  • Patent number: 10774341
    Abstract: The invention provides cotton event MON 88701, and plants, plant cells, seeds, plant parts, and commodity products comprising event MON 88701. The invention also provides polynucleotides specific for event MON 88701 and plants, plant cells, seeds, plant parts, and commodity products comprising polynucleotides specific for event MON 88701. The invention also provides methods related to event MON 88701.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: September 15, 2020
    Assignee: Monsanto Technology LLC
    Inventors: Ronald Joseph Brinker, Wen C. Burns, Paul C. C. Feng, John A. Kendig, Sherry LeClere, Jennifer Lutke, Marianne Malven
  • Patent number: 10772945
    Abstract: The invention relates to a novel VHH construct which can be bounded by a complete antibody without impairment of the antigen binding properties of the VHH construct being impaired. The invention also relates to an antibody construct comprising a VHH construct of this type and a kit, as well as the use thereof in immunodiagnostics or in the area of therapeutics. With the invention, among other things, it is possible to direct the existing immunity of a patient toward a different antigen.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: September 15, 2020
    Assignee: PRECLINICS GES. F. PRAEKLINISCHE FORSCHUNG MBH
    Inventors: Jonas Fuener, Angelo Bolchi, Erik Schliebs, Simone Ottonello
  • Patent number: 10758624
    Abstract: The present disclosure relates to an isolated compound including a phosphorothioated oligodeoxynucleotide (ODN) sequence conjugated to a short-activating RNA (saRNA) or an antisense oligonucleotide sequence (ASO), compositions of such a compound, and method of treatment of cancer and autoimmune diseases (with or without stimulating immune response), method of immune stimulation, method of activating CEBPA, and method of reducing activity of STAT transcription factor, by one of the disclosed compounds or compositions.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: September 1, 2020
    Assignee: CITY OF HOPE
    Inventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Dayson Friaca Moreira
  • Patent number: 10760070
    Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: September 1, 2020
    Assignee: CureVac Real Estate GmbH
    Inventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
  • Patent number: 10752651
    Abstract: Antimicrobial compounds and compositions of Formula (I) and methods of use are disclosed.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: August 25, 2020
    Assignee: Lakewood Amedex, Inc.
    Inventors: Randolph B. Sleet, Steven A. Kates, Steven Parkinson
  • Patent number: 10738365
    Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-151. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-151. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: August 11, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb, Xierong Wei
  • Patent number: 10716840
    Abstract: Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: July 21, 2020
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Lisa Bielke, Sherryll Layton, Billy Hargis, Neil R. Pumford, Olivia B. Faulkner, Luc Berghman, Daad Abi-Ghanem
  • Patent number: 10713383
    Abstract: Various methods and systems for processing at least some of genome sequences and at least some of associated information, for an individual, may be described and disclosed herein. A purpose of such processing may be to prevent, minimize, and/or mitigate against (1) identification of the individual from such genome sequence information and/or from associated information; and/or (2) using such genome sequence information and/or associated information as a basis for discriminating against the individual.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: July 14, 2020
    Inventor: Ethan Huang
  • Patent number: 10703782
    Abstract: Disclosed herein are nucleotide sequences encoding an insecticidal protein exhibiting Lepidopteran inhibitory activity, as well as novel insecticidal proteins referred to herein as a BCW 001, BCW 002, BCW 003, and BCW toxic protein-containing chimeras and BCW toxin insecticide, transgenic plants expressing the chimeras or the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: July 7, 2020
    Assignee: Monsanto Technology LLC
    Inventors: James A. Baum, David J. Bowen, Catherine A. Chay, David J. Chi, William P. Clinton, Crystal L. Dart, Leigh English, Stanislaw Flasinski, Victor M. Guzov, Kevin A. Jarrell, Uma R. Kesanapalli, Thomas M. Malvar, Robert M. McCarroll, Jason S. Milligan, Jay P. Morgenstern, Deborah G. Rucker, Sara A. Salvador, Temple F. Smith, Carlos E. Soto, Collin M. Stultz, Brian M. Turczyk, Ty T. Vaughn, Moritz W. F. Von Rechenberg
  • Patent number: 10696963
    Abstract: A method for optimising a nucleotide sequence for protein expression in a host cell, comprising the steps of: (a) constructing an expression library comprising a large number of variants of the sequence to be expressed operatively cloned in an expression vector, wherein (i) the sequence of the 6 nucleotides immediately upstream (5?-direction) of the first codon of the coding sequence to be expressed is completely or partially randomized; (ii) the sequence of the second and third codons of the coding sequence to be expressed is randomized, wherein the randomization of the second and third codons is limited to changes not altering the amino-acids encoded by said codons; (b) screening the library with regard to efficiency of protein expression in the host cell; and (c) selecting a sequence resulting in a desired level of efficiency of protein expression.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 30, 2020
    Assignee: CloneOpt AB
    Inventors: Daniel Daley, Kiavash Mirzadeh, Stephen Toddo, Suchithra Guntur
  • Patent number: 10696710
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: June 30, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhijian Chen, Lijun Sun, Jiaxi Wu, Heping Shi, Chuo Chen
  • Patent number: 10689653
    Abstract: Aspects of the disclosure relate to methods of altering RNA splicing in a subject. In some embodiments, methods are provided for correcting splicing in a cell that contains a DYSF gene having a mutation that results in defective splicing.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: June 23, 2020
    Assignee: University of Massachusetts
    Inventors: Robert H. Brown, Jr., Janice A. Dominov
  • Patent number: 10690685
    Abstract: A biosensing platform capable of high throughput mechanochemical biosensing comprising a DNA origami nanostructure having a plurality of slots into which recognition elements are strategically placed and apparatus that senses a change in the origami nanostructure in response to the introduction of a target where the apparatus includes a signal transduction unit and signal sensor which exploits mechanical signals in a recognition element which signal includes one or more mechanical tension or mechanochemical rearrangement event. The nanostructure is preferably a 2-dimensional or 3-dimensional arrangement of tiles linked by locking elements, such as aptamers that will open in response to an event such as exposure to a drug molecule, DNA, RNA or protein target.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: June 23, 2020
    Assignee: KENT STATE UNIVERSITY
    Inventors: Hanbin Mao, Deepak P. Koirala, Hiroshi Sugiyama, Masayuki Endo
  • Patent number: 10689693
    Abstract: The invention relates to a method and means for diagnosing tumors, in particular for an early diagnosis (prevention) and for differentiating between benign and malignant tumors using a PCR, in particular in bodily fluids. The method according to the invention is characterized by a combination of a pre-amplification process using a PCR, wherein methylated DNA sequences are amplified more strongly than non-methylated DNA sequences, and a subsequent quantification process using a special digital PCR, in which significantly more DNA is used than normally in the prior art. As comparison data indicates, the invention advantageously allows a clear reliable conclusion as to whether a malignant tumor disease is present or not. The invention is suitable for screening (prevention), monitoring the progress of a tumor disease, in particular to order to exclude a minimal residual disease (MRD), and for a differential diagnosis between malignant carcinoma and benign tumors.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 23, 2020
    Assignee: TECHNISCHE UNIVERSIT√ĄT DRESDEN
    Inventors: Mario Menschikowski, Albert Hagelgans, Gabriele Siegert
  • Patent number: 10675295
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: June 9, 2020
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Marc Abrams, Girish Chopda, Jihye Park
  • Patent number: 10669534
    Abstract: The present disclosure describes a nanoparticle comprising a three dimensional DNA nanocage and a payload biological macromolecule, and methods of assembly thereof.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: June 2, 2020
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jinglin Fu, Zhao Zhao, Neal Woodbury, Hao Yan
  • Patent number: 10669560
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: June 2, 2020
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10660911
    Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: May 26, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: James J. Collins, Kyle R. Allison, Mark P. Brynildsen
  • Patent number: 10648972
    Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art, including using a solid support, using mass spectrometry, and using quantitative polymerase chain reaction (Q-PCR).
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: May 12, 2020
    Assignee: SomaLogic, Inc.
    Inventors: James R. Heil, Daniel J. Schneider, Daniel T. Nieuwlandt, Sheri K. Wilcox, Dominic Zichi, Todd Gander, Bruce Eaton, Larry Gold
  • Patent number: 10640791
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: May 5, 2020
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10640769
    Abstract: Described are post transcriptionally chemically modified double strand RNAs (MdsRNAs) having more than 30 base pairs. The MdsRNAs inhibit gene expression in target organisms. Also described are methods of making and using MdsRNAs.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: May 5, 2020
    Assignee: nanoSUR LLC
    Inventors: Juan P. Arhancet, Sreevishnu Cheerla, Graciela B. Arhancet, David B. Rozema
  • Patent number: 10633411
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: April 28, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhijian Chen, Lijun Sun, Jiaxi Wu, Heping Shi, Chuo Chen
  • Patent number: RE48468
    Abstract: The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least one adjunct compound for improving muscle fiber function, integrity and/or survival.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: March 16, 2021
    Assignees: BioMarin Technologies B.V., Academisch Ziekenhuis Leiden
    Inventors: Josephus Johannes De Kimpe, Gerard Johannes Platenburg, Judith Christina Theodora Van Deutekom, Annemieke Aartsma-Rus, Garrit-Jan Boudewijn Van Ommen